Chiara P.
- Country
- Italy
- Department
- Neurology Unit
Research Overview
- A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Subjects Diagnosed With Epilepsy (X-TOLE4)
- Efficacy and Safety Evaluation of PRAX-628 in Adults with Focal Epilepsy: A Double-Blind, Randomized, Multicenter Trial
- Evaluation of the Safety, Tolerability, and Efficacy of Azetukalner as Adjunctive Therapy in Adults with Focal-Onset Epilepsy: A Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 74 of 98 partner sites.
Specializations
Primary Epilepsy Management
This investigator specializes in treating primary generalized tonic-clonic seizures (PGTCS), focusing on developing innovative therapeutic approaches for patients with severe seizure disorders.
- Generalized seizure control
- Advanced anticonvulsant therapies
- Treatment-resistant PGTCS
Particular emphasis is placed on evaluating novel therapeutic compounds for seizure frequency reduction in PGTCS patients.
Focal Epilepsy Research
The investigator has extensive experience in focal epilepsy treatment, particularly focusing on adult patients with partial onset seizures requiring multiple anti-seizure medications.
- Focal seizure management
- Combination therapy approaches
- Adult epilepsy care
Their work encompasses the evaluation of therapeutic interventions for patients with medication-resistant focal epilepsy.
Comprehensive Epilepsy Care
This specialist conducts research in long-term epilepsy management, addressing both focal-onset seizures and PGTCS through innovative treatment protocols.
- Extended therapy evaluation
- Multiple seizure type treatment
- Safety monitoring protocols
The investigator's work includes assessment of therapeutic interventions across various seizure manifestations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.